Printer Friendly
The Free Library
22,728,043 articles and books

Advanced Medical Diagnostics: Histoscanning Accurately Locates and Characterises Prostate Cancer Foci.

A Breakthrough in Ultrasound Data Processing Technology May Be Set to Redefine the Role of Non-Invasive Imaging in Diagnosis, Staging, Treatment and Monitoring of Prostate Cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men.  

WATERLOO, Belgium -- HistoScanning[TM], a novel processing technology for ultrasonography ultrasonography /ul·tra·so·nog·ra·phy/ (-so-nog´rah-fe) the imaging of deep structures of the body by recording the echoes of pulses of ultrasonic waves directed into the tissues and reflected by tissue planes where there is a change in  shows high accuracy in the characterisation and localisation (programming) localisation - (l10n) Adapting a product to meet the language, cultural and other requirements of a specific target market "locale".

Localisation includes the translation of the user interface, on-line help and documentation, and ensuring the images and
 of prostate cancer foci, according to a study published in the British Journal of Urology The British Journal of Urology is a leading urological journal. It is published at Oxford by Blackwell Science, Ltd. The editor in 2003 is Hugh Whitfield. The British Journal of Urology is the official journal of the British Association of Urological Surgeons.  International (BJUI) this week.

HistoScanning of the prostate was performed on 29 men scheduled to undergo radical prostatectomy and results were subsequently compared to the corresponding detailed histology. The study showed that HistoScanning accurately measured the diameter of the largest tumour (r=0.95, p<0.0001) and in all cases correctly attributed the presence of multiple foci, the laterality laterality
 or hemispheric asymmetry

Characteristic of the human brain in which certain functions (such as language comprehension) are localized on one side in preference to the other.
 of the disease and the involvement of the prostate capsula capsula /cap·su·la/ (kap´su-lah) pl. cap´sulae   [L.] capsule.

n. pl. cap·su·lae

Although more extensive trials are needed to fully validate its role in routine clinical practice, experts involved in the study believe that HistoScanning has the potential to address important challenges in the diagnosis, staging, treatment and monitoring of men with suspected prostate cancer.

Mr. Mark Emberton of the Division of Surgery and Interventional Science at the University College London “UCL” redirects here. For other uses, see UCL (disambiguation).
University College London, commonly known as UCL, is the oldest multi-faculty constituent college of the University of London, one of the two original founding colleges, and the first British
 and co-author explained: "Today 75% of all biopsies are negative and therefore provide no useful diagnostic information. Due to its geometric and spatial accuracy, HistoScanning shows great potential for directing biopsies and focal treatment to the largest tumour bulk and hence improve procedure efficiency." He continued: "The detection and visualisation of multiple foci throughout the prostate and capsula may enhance the staging of lesions and optimise treatment selection".

Dr. Johan Braeckman, Head of Unit at the Urology Department of the University Hospital Brussels and principal investigator for the study sees two further important uses: "HistoScanning may help reassure men with elevated PSA (Professional Services Automation) An information system designed to organize, track and manage all opportunities, work, resources, costs, revenues and invoices to improve the productivity and efficiency of the workforce.  that they don't have clinically relevant prostate cancer." He further noted: "Men with less aggressive prostate cancers are increasingly offered active surveillance in order to postpone or avoid radical treatment that is associated with the risk of erectile dysfunction and incontinence. HistoScanning may actually facilitate such monitoring and reduce the need for painful and sometimes toxic repeat biopsies." Braeckman concluded: "It seems that in addition to removing diagnostic uncertainty and patient anxiety, HistoScanning has a realistic potential to save costs in health care provision."

About HistoScanning

HistoScanning is a diagnosis support tool designed to detect, visualise and characterise cancers in solid organs. It is used in conjunction with specific commercially available ultrasound systems capable of acquiring and transferring so called volumetric volumetric /vol·u·met·ric/ (vol?u-met´rik) pertaining to or accompanied by measurement in volumes.

Of or relating to measurement by volume.
 Radio Frequency (RF) data. The proprietary tissue characterisation algorithms can either be applied to discrete regions of interest or the entire scanned tissue volume. Suspicious areas are highlighted in HistoScanning's 3D image viewer.

HistoScanning is developed and commercialized by Advanced Medical Diagnostic s.a., a privately held company privately held company

A firm whose shares are held within a relatively small circle of owners and are not traded publicly.
 based in Waterloo, Belgium. The company aims to improve cancer diagnostics in a clinically meaningful and cost effective manner.

HistoScanning for the prostate is under clinical evaluation. Its commercial debut is expected in 2008.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved.

 Reader Opinion




Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 9, 2007
Previous Article:Research and Markets: Amgen Inc. Took in a Net Profit of $2,950 Million in Fiscal Year 2006, a Decrease of 19.7% over 2005.
Next Article:The Public Service Aviation Handbook 2007-08 is Available Now.

Related Articles
The neglected sex gland: a protein in the blood forecasts cancer of the prostate.
Saving black men.
Blood test to detect lung cancer.
Outcomes Data Continue to Demonstrate Value of Cytogen's PROSTASCINT(R) to Predict Prognosis in Prostate Cancer.
Cytogen Announces Initiation of Phase 1 Trial for Radiolabeled Antibody for the Treatment of Hormone-Refractory Prostate Cancer.
Outcomes Data Demonstrating Prognostic Value of Cytogen's PROSTASCINT Published in Peer-Reviewed Journal Urology.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters